STOCK TITAN
  1. Home
  2. News
  3. ENTX

Entera Bio Ltd. Ordinary Shares - ENTX STOCK NEWS

Welcome to our dedicated page for Entera Bio Ltd. Ordinary Shares news (Ticker: ENTX), a resource for investors and traders seeking the latest updates and insights on Entera Bio Ltd. Ordinary Shares stock.

Entera Bio Ltd. (ENTX) is a biotechnology firm based in Israel, specializing in the development of orally delivered macromolecule therapeutics. These include peptides and therapeutic proteins aimed at treating chronic medical conditions with an unmet need. The company’s innovative approach focuses on oral administration, which has the potential to significantly change treatment paradigms.

Entera Bio's leading product candidates include EB613 and EB612. EB613 is designed to treat osteoporosis in a once-daily, oral mini tablet form of synthetic human PTH (1-34) (teriparatide). It has shown promising results in Phase 2 clinical trials, meeting both primary and secondary endpoints. Entera Bio plans to initiate a Phase 3 study for EB613 in 2024, following FDA guidelines. EB612 is being developed as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism.

Beyond these, Entera Bio is advancing several other oral peptide therapies. These include an oral oxyntomodulin tablet for obesity and an oral GLP-2 peptide tablet for rare malabsorption conditions like short bowel syndrome, in collaboration with OPKO Health.

Entera Bio leverages a proprietary technology platform that boosts the oral bioavailability of peptides, making them effective alternatives to injectable therapies. This platform is pivotal in their ongoing projects and future pipeline products, which they aim to bring to clinical phases by 2025.

In terms of financials, Entera Bio has demonstrated robust performance, as reflected in their latest financial results for the year ending December 31, 2023. The company continues to focus on strategic partnerships and advancing their research to fulfill significant unmet medical needs.

For the latest updates and news about Entera Bio Ltd., including their latest product developments and financial results, visit Entera Bio's official website.

News

Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months

Rhea-AI Summary
Entera Bio (NASDAQ: ENTX) announces FDA's communication regarding the qualification of bone mineral density as a surrogate endpoint for fractures in future trials of new anti-osteoporosis drugs. The proposed Phase 3 study for EB613, Entera's lead clinical candidate, aims to meet the SABRE quantitative BMD thresholds. If successful, EB613 could be the first oral tablet osteoanabolic treatment, potentially revolutionizing osteoporosis treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
clinical trial
-
News

Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

Rhea-AI Summary
Entera Bio (NASDAQ: ENTX) announces positive pharmacokinetic results from its collaborative research with OPKO Health, Inc. on a long-acting GLP-2 agonist using Entera's N-Tab™ technology. The program aims to develop an oral tablet alternative for GLP-2 therapy, potentially revolutionizing treatment for patients with short bowel syndrome and related conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.8%
Tags
none
-
News

Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

Rhea-AI Summary
Entera Bio Ltd. (NASDAQ: ENTX) reported financial results and key updates for 2023, highlighting advancements in oral peptide programs like EB613 for osteoporosis and EB612 for hypoparathyroidism. The company aims to develop innovative treatments addressing unmet medical needs, with potential catalysts in 2024. Financially, Entera had $11.0 million in cash as of December 31, 2023, projecting operational funding until mid-2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.04%
Tags
earnings
News

Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Rhea-AI Summary
Entera Bio Ltd. (NASDAQ: ENTX) has successfully regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2), ensuring continued listing on The NASDAQ Capital Market. The Company's ordinary shares maintained a minimum closing bid price of $1.00 or more for 10 consecutive business days, reaching this milestone on March 1st, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.44%
Tags
none
-
News

Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Rhea-AI Summary
Entera Bio Ltd. (NASDAQ: ENTX) will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference, presenting a business overview and update by CEO Miranda Toledano. The virtual event will take place on February 13-14, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
conferences
-
News

Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule

Rhea-AI Summary
Entera Bio Ltd. (NASDAQ: ENTX) received a 180-day extension from Nasdaq to regain compliance with the minimum $1.00 bid price requirement. The company has until June 24, 2024, to meet the requirement. Failure to do so may result in delisting from Nasdaq.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
none
News

Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025

Rhea-AI Summary
Entera Bio Ltd. (NASDAQ: ENTX) closed a private placement, issuing and selling 7,916,879 units at $0.835 per unit, raising approximately $6.6 million in gross proceeds. The five-year warrants represent a 41% premium to the Nasdaq closing price per ordinary share on December 20, 2023, with potential additional proceeds of approximately $7.9 million if all warrants are exercised. The Company intends to use the net proceeds for general working capital purposes, extending its cash runway into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
none
-
News

Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide Platform

Rhea-AI Summary
Entera Bio Ltd. (NASDAQ: ENTX) reported interim data from a Phase 1 study on its oral peptide platform, displaying optimal profiles for osteoporosis treatment. The study compared EB613 with injectable PTH(1-34), showing superior bioavailability and consistent pharmacokinetic and pharmacodynamic effects. New compositions also demonstrated enhanced bioavailability and rapid PD responses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
clinical trial
-
News

Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development

Rhea-AI Summary
Entera Bio Ltd. (NASDAQ: ENTX) reported corporate updates and financial results for Q3 2023, highlighting their oral peptide programs, including EB613 for osteoporosis and intense sports injuries, and EB612 for hypoparathyroidism. They also announced a transformative collaboration with OPKO Health, Inc. to develop GLP-2 for short bowel syndrome and oxyntomodulin for obesity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
earnings
News

Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis

Rhea-AI Summary
Entera Bio Ltd. (NASDAQ: ENTX) reports that the ASBMR has submitted a qualification plan to the FDA to use the treatment-related change in bone mineral density (BMD) as a surrogate endpoint for fractures in future trials of new anti-osteoporosis drugs. This is a critical step for osteoporosis drug innovation and could potentially impact the development of EB613, the first oral, osteoanabolic once-daily tablet treatment for osteoporosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.66%
Tags
clinical trial

FAQ

What is the current stock price of Entera Bio Ltd. Ordinary Shares (ENTX)?

The current stock price of Entera Bio Ltd. Ordinary Shares (ENTX) is $2.1 as of December 20, 2024.

What is the market cap of Entera Bio Ltd. Ordinary Shares (ENTX)?

The market cap of Entera Bio Ltd. Ordinary Shares (ENTX) is approximately 81.0M.

What is Entera Bio Ltd.?

Entera Bio Ltd. is an Israeli biotechnology company specializing in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins.

What are Entera Bio's main product candidates?

Entera Bio's main product candidates include EB613 for osteoporosis and EB612 for hypoparathyroidism, both delivered in oral mini tablet forms.

What is unique about Entera Bio's approach?

Entera Bio's unique approach involves the oral administration of peptides and proteins using a proprietary platform, offering an alternative to injectable therapies.

What is EB613?

EB613 is an oral mini tablet form of synthetic human PTH (1-34) (teriparatide) developed for the treatment of osteoporosis.

What stage is EB613 currently in?

EB613 is preparing for a Phase 3 registrational study, following successful Phase 2 clinical trials.

What is EB612?

EB612 is an oral mini tablet form of PTH(1-34) peptide being developed for the treatment of hypoparathyroidism.

Who are Entera Bio's partners?

Entera Bio collaborates with OPKO Health to develop an oral GLP-2 peptide tablet for conditions like short bowel syndrome.

What is Entera Bio's financial performance?

Entera Bio has shown robust financial performance, with recent results reported for the year ending December 31, 2023.

Where can I find more information about Entera Bio?

For more details, visit Entera Bio's official website at www.enterabio.com.

What other projects is Entera Bio working on?

Entera Bio is also developing oral peptide therapies for obesity and other rare malabsorption conditions.

Stock ENTX logo
Entera Bio Ltd. Ordinary Shares

Nasdaq:ENTX

ENTX Rankings

#4558 Ranked by Market Cap
N/A Ranked by Dividends

ENTX Stock Data

81.03M
29.75M
19.02%
18.94%
0.14%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
JERUSALEM